Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

S cientists at Merck are staring down a drug development puzzle. One that has to do with a mutated protein called PCSK9, which is associated with the production of harmful levels of cholesterol in ...

Merck’s broad, global Phase 3 program for MK-0616 aims to enroll approximately 17,000 participants across the CORALreef Lipids, CORALreef HeFH and CORALreef Outcomes studies. About PCSK9 and MK-0616 ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Johns said Merck leveraged mRNA display to screen large libraries of cyclic peptide molecules and their ability to bind to PCSK9. He explained, “Merck’s team optimized these molecules into ...

Merck's oral PCSK9 is also much further along in development, with late-stage trial data expected this year. Early data also suggests Merck's drug could be more effective than AstraZeneca's ...

Merck's Q1 2023 earnings exceeded expectations, ... Merck's clinical pipeline shows promise with advancing candidates, including Sotatercept and oral PCSK9 inhibitor MK-0616.

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Merck’s broad, global Phase 3 program for MK-0616 aims to enroll approximately 17,000 participants across the CORALreef Lipids, CORALreef HeFH and CORALreef Outcomes studies. About PCSK9 and MK-0616 ...